中国P站

Targeted therapy; Bone sarcoma; Osteosarcoma; Ewing sarcoma; Chondrosarcoma; Precision medicine; Molecular profiling; Tyrosine kinase inhibitors; Immunotherapy; Orthopedic oncology

Introduction

Bone sarcomas are a group of malignant tumors that arise from bone-forming or cartilage-producing cells. The most common subtypes include osteosarcoma, Ewing sarcoma, and chondrosarcoma. These cancers often affect young individuals and are characterized by high rates of local invasion and distant metastasis [1]. Standard treatment protocols, including surgical resection and systemic chemotherapy, have significantly improved survival for localized disease. However, the prognosis for patients with metastatic or recurrent bone sarcomas remains dismal, highlighting the need for novel therapeutic approaches. Recent advances in genomic technologies have revealed critical molecular drivers in bone sarcomas, opening the door for the integration of targeted therapy into routine care. This strategy focuses on interfering with tumor-specific signaling pathways, growth factors, and genetic abnormalities to inhibit tumor progression and improve outcomes [2].

Description

Targeted therapies function by specifically inhibiting molecules and pathways that are dysregulated in cancer cells. In bone sarcomas, several targets have been identified, including receptor tyrosine kinases (RTKs), cell cycle regulators, and pathways related to angiogenesis, apoptosis, and immune evasion.

Osteosarcoma: The molecular landscape of osteosarcoma is complex, characterized by a high level of genomic instability. Aberrations in the PI3K/AKT/mTOR pathway, overexpression of HER2, VEGF, and PDGFR, and alterations in RB1 and TP53 genes have been implicated. Targeted agents such as mTOR inhibitors (e.g., everolimus), VEGF inhibitors (e.g., bevacizumab), and multi-kinase inhibitors (e.g., sorafenib, regorafenib) have shown some clinical activity, particularly in refractory settings [3].

Ewing Sarcoma: Driven by characteristic fusion proteins such as EWS-FLI1, Ewing sarcoma presents unique opportunities for targeted interventions. Though direct inhibition of fusion proteins remains challenging, downstream targets such as IGF-1R, CDK4/6, and epigenetic regulators have been explored. IGF-1R inhibitors (e.g., ganitumab) have demonstrated modest efficacy in clinical trials, with ongoing studies evaluating combination regimens [4].

Chondrosarcoma: This tumor subtype is typically resistant to conventional chemotherapy. Mutations in IDH1/2, COL2A1, and EXT genes are common. Targeted therapies under investigation include IDH inhibitors (e.g., ivosidenib), hedgehog pathway inhibitors, and immune checkpoint inhibitors in certain subtypes. The integration of next-generation sequencing (NGS) and other molecular diagnostic tools has enabled the identification of actionable mutations, facilitating the selection of appropriate targeted agents. This approach supports the paradigm shift toward personalized medicine in orthopedic oncology [5].

Discussion

Integrating targeted therapy into the management of bone sarcomas requires a multidisciplinary effort involving oncologists, orthopedic surgeons, radiologists, pathologists, and molecular biologists. The following considerations are critical for successful implementation:

Patient Selection: Not all patients are candidates for targeted therapy. Molecular profiling must be performed to identify those with targetable mutations or pathway activations. Comprehensive genomic panels and liquid biopsy can aid in this process [6].

Therapeutic Timing: Targeted therapies may be administered as monotherapy in refractory disease or as adjuncts to conventional chemotherapy and surgery. The optimal timing and sequencing of these agents remain under investigation.

Combination Therapies: Given the heterogeneity and adaptive resistance of bone sarcomas, combination therapies targeting multiple pathways are being explored. For example, combining mTOR inhibitors with VEGF blockers or immune checkpoint inhibitors may enhance efficacy.

Clinical Trials: Participation in clinical trials remains crucial for advancing the understanding and use of targeted therapies. Numerous trials are evaluating novel agents, biomarkers, and combination regimens specific to bone sarcomas [7].

Resistance Mechanisms: As with other cancers, bone sarcomas can develop resistance to targeted therapy. Secondary mutations, activation of compensatory pathways, and tumor microenvironment factors contribute to therapeutic failure. Research into resistance mechanisms is essential to developing next-generation inhibitors and adaptive treatment strategies [8].

Safety and Toxicity: While generally more tolerable than traditional chemotherapy, targeted therapies can still produce side effects such as hypertension, fatigue, skin toxicity, and hematologic abnormalities. Monitoring and managing these toxicities are vital for maintaining quality of life and adherence to treatment [9].

Access and Cost: Targeted therapies can be expensive and may not be readily accessible in all healthcare settings. Equitable access requires policy initiatives and inclusion of these therapies in standard treatment guidelines. Case reports and early-phase studies have highlighted the potential of targeted therapies in extending progression-free survival and improving quality of life in select patients with bone sarcomas. However, large-scale, randomized studies are needed to validate these findings and define standardized protocols [10].

Conclusion

The integration of targeted therapy into the management of bone sarcomas marks a significant advancement in orthopedic oncology. By aligning treatment strategies with the unique molecular profile of each tumor, clinicians can offer more precise and potentially more effective interventions. While challenges such as resistance, cost, and limited efficacy in unselected populations persist, ongoing research and clinical trials are paving the way for a more personalized and hopeful future for patients with bone sarcomas. As molecular diagnostics become increasingly sophisticated and accessible, targeted therapy is expected to become an essential component of multidisciplinary cancer care, ultimately transforming the prognosis and experience of individuals affected by these rare but aggressive malignancies.

References

1. Bannon S, Gonsalvez CJ, Croft RJ, Boyce PM (2002) . Psychiatry Res 110: 165-174.

   , ,

2. Bestelmeyer PE, Phillips LH, Crombiz C, Benson P, Clair DS, et al. (2009) . Psychiatry res 169: 212-219.

   , , Crossref

3. Chambers CD, Bellgrove MA, Stokes MG, Henderson TR, Garavan H, et al. (2006) . J Cogn Neurosci 18: 444-455.

   , , Crossref

4. Badcock JC, Michie PT, Johnson L, Combrinck J (2002) . Psychol Med 32: 287-297.

   , , Crossref

5. Bleuler E (1958) .

6. Bellgrove MA, Chambers CD, Vance A, Hall N, Karamitsios M, et al. (2006) . Psychol Med 36: 495-505.

   , , Crossref

7. Carter CS, Barch DM (2007) . Schizophr Bull 33: 1131-1137.

   , ,

8. Aron AR (2011) . Biol psychiatry 69: e55-e68.

   , ,

9. Blasi G, Goldberg TE, Weickert T, Das S, Kohn P, et al. (2006) . Eur J Neurosci 23: 1658-1664.

   , , Crossref

10. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP, et al. (1992) . J Neurosci 12: 924-929.

    , , Crossref